Kimes Kate, Beasley Knox, Dalton Scott R
San Antonio Military Medical Center, Fort Sam Houston.
Dermatol Online J. 2015 Sep 17;21(9):13030/qt8kw141mb.
Dovitinib (TKI258) is a multi-targeted receptor tyrosine kinase inhibitor currently under clinical trials for a wide variety of cancers. Well-known side effects include nausea, vomiting, diarrhea, and fatigue. To date, there have only been only two reported cases with skin manifestations as a side effect. We report a case of eruptive facial milia and comedones in the setting of dovitinib treatment for metastatic gastrointestinal cancer. This case is unique as the clinical presentation was more rapid in onset and showed an absence of inflammatory lesions. Although the pathogenesis for skin manifestations is presently unknown, we present this case to increase awareness of potentially under-reported cutaneous side effects.
多韦替尼（TKI258）是一种多靶点受体酪氨酸激酶抑制剂，目前正处于针对多种癌症的临床试验阶段。其众所周知的副作用包括恶心、呕吐、腹泻和疲劳。迄今为止，仅有两例报告显示皮肤表现为副作用。我们报告一例在使用多韦替尼治疗转移性胃肠道癌时出现爆发性面部粟丘疹和粉刺的病例。该病例独特之处在于临床表现起病更快且无炎症性皮损。尽管目前皮肤表现的发病机制尚不清楚，但我们呈现此病例以提高对可能未充分报告的皮肤副作用的认识。
